Actively Recruiting
Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108
Led by Novo Nordisk A/S · Updated on 2026-03-06
91
Participants Needed
1
Research Sites
110 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study looks at the safety and blood levels of the study drug INV-347 in participants who were previously dosed with INV-347 in study INV-CL-108. Participants will not get any study drug in this study as it looks into the safety of a drug previously dosed. The study will last until visit 21.
CONDITIONS
Official Title
Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Informed consent obtained before any study-related activities
- Male or female (sex at birth)
- Age 18 years or above at the time of signing the informed consent
- Previously dosed with INV-347 in study INV-CL-108 and with measurable INV-347 concentration in plasma at enrolment (above lower limit of qualification of 0.5 ng/mL)
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Syneos Health Clinique
Québec, Canada, G1P 0A2
Actively Recruiting
Research Team
N
Novo Nordisk
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here